Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas

Published:2014-06-01 Issue:7 Volume:31 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Wu Jianyuan,Li Qingdi Quentin,Zhou Huiping,Lu Yinying,Li Jueli M.,Ma Yao,Wang Li,Fu Tingting,Gong Xingjiang,Weintraub Michael,Wu Shuangchan,Ding Hong

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-014-0014-8.pdf

Reference41 articles.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

2. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145–50.

3. Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol. 2005;97:110–7.

4. Zhou J, Liu M, Luthra R, Jones J, Aneja R, Chandra R, Tekmal RR, Joshi HC. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother Pharmacol. 2005;55:461–5.

5. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 2011;11:377–83.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The latest research progress: Active components of Traditional Chinese medicine as promising candidates for ovarian cancer therapy;Journal of Ethnopharmacology;2025-01

2. Dapagliflozin alleviates renal podocyte pyroptosis via regulation of the HO‑1/NLRP3 axis;Molecular Medicine Reports;2023-09-08

3. The IC-50-time evolution is a new model to improve drug responses consistency of large scale studies;F1000Research;2022-03-07

4. Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis;Stem Cell Research & Therapy;2021-11-12

5. Mechanisms and Advances in Anti-Ovarian Cancer with Natural Plants Component;Molecules;2021-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3